Human induced pluripotent stem cell (hiPSC) culture has become routine, yet pluripotent cell media costs, frequent media changes, and reproducibility of differentiation have remained restrictive, limiting the potential for large-scale projects. Here, we describe the formulation of a novel hiPSC culture medium (B8) as a result of the exhaustive optimization of medium constituents and concentrations, establishing the necessity and relative contributions of each component to the pluripotent state and cell proliferation. B8 eliminates 97% of the costs of commercial media, made possible primarily by the in-lab generation of three E. coli-expressed, codon-optimized recombinant proteins: an engineered form of fibroblast growth factor 2 (FGF2) with improved thermostability (FGF2-G3); transforming growth factor β3 (TGFβ3) -a more potent TGFβ able to be expressed in E. coli; and a derivative of neuregulin 1 (NRG1) containing the EGFlike domain. The B8 formula is specifically optimized for fast growth and robustness at low seeding densities. We demonstrated the derivation of 29 hiPSC lines in B8 as well as maintenance of pluripotency long-term, while conserving karyotype stability. This formula also allows a weekend-free feeding schedule without sacrificing growth rate or capacity for differentiation.
Introduction
Human induced pluripotent stem cells (hiPSCs) are functionally immortal and can proliferate without limit while maintaining the potential to differentiate to, hypothetically, all ~220 cell lineages within the human body. hiPSC generation has become routine due to the simplicity of amplification of CD71 + blood proerythroblasts (Chou et al., 2015; Chou et al., 2011; Tan et al., 2014) or myeloid cells (Eminli et al., 2009; Staerk et al., 2010) and commercial Sendai virus-based reprogramming factor expression (Fujie et al., 2014; Fusaki et al., 2009) . This simplicity has resulted in increased enthusiasm for the potential applications of hiPSC-derived cells across many fields, including regenerative medicine, disease modeling, drug discovery, and pharmacogenomics.
However, these applications require the culture of either large quantities of hiPSCs or hiPSC lines derived from large numbers of patients, and three major restrictions have become evident: 1, the cost of large-scale pluripotent cell culture, which is prohibitive for high patientnumber projects; 2, the time-consuming requirement for daily media changes, which is particularly problematic for laboratories in industry; 3, inter-line variability in differentiation efficacy, which is highly dependent on pluripotent culture consistency and methodology. Our understanding of the media conditions required to culture human pluripotent stem cells has progressed steadily over the last 15 years, with significant breakthroughs coming from the discovery of the necessity for high concentrations of FGF2 (Xu et al., 2005) , the use of TGFβ1 (Amit et al., 2004) , and the elimination of knockout serum replacement (KSR) with the TeSR formula which contains 19 components (Ludwig and Thomson, 2007; Ludwig et al., 2006a; Ludwig et al., 2006b) , followed by the first robust chemically defined formula, E8 (Beers et al., 2012; Chen et al., 2011) which consists of just 8 major components. A number of alternative non-chemically defined pluripotent formulations have been described including: CDM-BSA Vallier et al., 2005; Vallier et al., 4 2009 ), DC-HAIF (Singh et al., 2012; Wang et al., 2007) , hESF9T (Furue et al., 2008; Yamasaki et al., 2014) , FTDA (Breckwoldt et al., 2017; Frank et al., 2012; Piccini et al., 2015) , and iDEAL (Figure S1A) .
Each of the available formulations consist of a core of three major signaling components: 1, insulin or IGF1 which bind INSR and IGF1R to signal the PI3K/AKT pathway promoting survival and growth; 2, FGF2 and/or NRG1 which bind FGFR1/FGFR4 or ERBB3/ERBB4 respectively, activating the PI3K/AKT/mTOR and MAPK/ERK pathways; and 3, TGFβ1, NODAL, or activin A which bind TGFBR1/2 and/or ACVR2A/2B/1B/1C to activate the TGFβ signaling pathway. NODAL is used less commonly in pluripotent media formulations due to the expression of NODAL antagonists LEFTY1/2 in human pluripotent stem cells (hPSC) (Besser, 2004; Sato et al., 2003) resulting in a requirement for high concentrations in vitro (Chen et al., 2011) . In addition, numerous growth factor-free formulae utilizing small molecules to replace some or all growth factors in hPSC culture have been described (Burton et al., 2010; Desbordes et al., 2008; Kumagai et al., 2013; Tsutsui et al., 2011) , however, these have not successfully translated to common usage. Recently, a growth factor-free formula AKIT was demonstrated (Yasuda et al., 2018) , combining inhibitors of GSK3B (1-azakenpaulone), DYRK1 (ID-8), and calcineurin/NFAT (tacrolimus/FK506), albeit with much reduced proliferation and colony growth, as well as increased interline variability in growth. Finally, more than 15 commercial pluripotent media are also available in which the formulae are proprietary and not disclosed to researchers.
These media represent the major cost for most hiPSC labs and considerably restrict research efforts. Some of these media formulae are suggested to support hiPSC growth without daily media changes or 'weekend-free', likely by using heparin sulfate to stabilize FGF2 that otherwise degrades quickly at 37 °C Furue et al., 2008) and including bovine serum albumin (BSA) which acts as a multifaceted antioxidant. 6 dilution) ( Figure S1A ) and were subsequently used at a conservative 1:800 dilution for all future experiments.
We next established a suitable pluripotent growth assay modeled on that used by Ludwig et al. and Chen et al. after establishing that neither automated cell counting of dissociated cells (6well) or small format survival assays (i.e. 96-well) were suitably robust (Figure 1B) . We utilized this 6-day protocol rather than our typical 4-day protocol to enhance the detection of variance between formulae during sub-optimal low-density culture. All initial experiments were performed using a version of FGF2 we generated in-house with a mutation (K128N ) previously demonstrated to enhance thermostability . In a first round of optimizations we assessed a range of concentrations for each of the six major hiPSC medium components (Figures 1C-H) . During this stage we established that insulin was essential and could only be replaced by very high levels of IGF1 LR3 (≥1 µg ml -1 ), although this was not cost-effective ( Figure 1C) . The effect of insulin was dose-dependent up to 20 µg ml -1 . Ascorbic acid 2-phosphate was not essential, as previously demonstrated (Prowse et al., 2010) , but higher levels (≥200 µg ml -1 ) enhanced growth ( Figure   1D ). Of note, this level of ascorbic acid 2-phosphate is similar to the level optimized in the cardiac differentiation media CDM3 (Burridge et al., 2014) . Transferrin was also not essential to the media formula, but improved growth in a dose-dependent manner with 20 µg ml -1 exhibiting optimal growth while maintaining cost-efficiency ( Figure 1E) . A source of selenium was shown to be essential, although concentrations of sodium selenite between 2-200 ng ml -1 did not significantly affect growth, and sodium selenite became toxic at ≥200 ng ml -1 (Figure 1F ). FGF2-K128N was optimal at ≥40 ng ml -1 (Figure 1G) , and TGFβ1 was sufficient at ≥0.5 ng ml -1 in this simple one passage growth assay ( Figure 1H ).
Optimization of Additional Media Components
In previous work, Chen et al. show that transferrin improves single cell clonality in the absence of the Rho-associated kinase (ROCK1/2) inhibitor Y27632. We could not replicate this observation in our assay (Figure 2A) suggesting that the inclusion of a ROCK1/2 inhibitor for at least the first 24 h after passage is optimal. We also confirmed that the addition of 2 µM thiazovivin for the first 24 h marginally, though not significantly, improved growth over 10 µM Y27632 and was ~5 ´ more cost-effective choice (Figure 2B) . Some recent hiPSC growth formulae have suggested that the addition of high levels (2 ´) of non-essential amino acids (NEAA) and/or low levels (0.1 ´) of chemically defined lipids enhance growth ( Figure S1B) . In our assay NEAA did not augment growth and the addition of lipids was inhibitory at all but the lowest levels ( Figure 2C) .
Supplementation with bovine serum albumin (BSA), a common hPSC media component, did not have positive or negative effects on growth and was excluded to maintain a chemically defined formula ( Figure 2D) . The DMEM/F12 basal media we use from Corning contains higher levels of sodium bicarbonate (~29 mM or 2438 mg l -1 ) compared to DMEM/F12 from other manufacturers (Figure S1C). Supplementation of Gibco DMEM/F12, which contains 14 mM of sodium bicarbonate, with 20 mM of additional sodium bicarbonate has recently been demonstrated to be advantageous to hiPSC growth rate by suppressing acidosis of the medium (Liu et al., 2018) .
In our hands, the standard 29 mM of sodium bicarbonate was optimal (Figure 2E) . We also assayed the effect of pH and osmolarity on growth and found that pH 7.1 (Figure 2F) and an osmolarity of 310 mOsm l -1 (Figure 2G ) to promoted the highest growth rate in contrast to pH 7.2 and 350 mOsm l -1 demonstrated by Ludwig et al. (Ludwig et al., 2006b) or pH 7.4 and 340 mOsm l -1 used by Chen et al. (Chen et al., 2011) . Of interest here, low osmolarity KnockOut DMEM (270 mOsm l -1 ) has historically been used for mESC culture based on the approximation of mouse embryonic tissue (Lawitts and Biggers, 1992) . All of our experiments were optimized for 5% O2 and 5% CO2, a common compromise for optimal hypoxia which enhances reprograming efficiency (Chen et al., 2011) , pluripotency (Forristal et al., 2010) , and genome stability (Narva et al., 2013) without the significant cost increase from high N2 usage or from 10% CO2 suggested by some (Ludwig et al., 2006b) , that necessitates higher levels of sodium bicarbonate.
In our original hiPSC culture medium formula, we used commercial recombinant human FGF2, and this accounted for >60% of the media cost. This led us to investigate the production of FGF2 in-house, for which we generated a FGF2 sequence with E. coli-optimized codon usage to enhance yield and a K128N point mutation to improve thermostability . This sequence was inserted into a recombinant protein production plasmid (pET-28a) utilizing dual 6´His tags that were not cleaved during purification (Figure S2) . We subsequently generated two additional thermostable FGF2 variants: FGF1-4X , and FGF2-G3 (Dvorak et al., 2018) . We found FGF2-G3, with nine point-mutations was more potent than FGF2-K128N, showing a similar effect on growth rate at 5 ng ml -1 to FGF2-K128N at 100 ng ml -1 (Figure 2H ).
Optimization of Media Components using a Long-Term Assay
Our initial short-term experiments were useful for preliminary optimizations, yet we were aware from previous experiments that some variables, such as the elimination of TGFβ1, had minimal effects short-term and would only have detectable negative effects in long-term experiments. We began a second round of optimizations using a long-term version of our growth assay covering 5 passages ( Figure 3A) . Each experiment was independently repeated at least 5 times. These experiments again confirmed optimal concentrations of insulin (20 µg ml -1 ; Figure 3B ), ascorbic acid 2-phosphate (200 µg ml -1; Figure 3C ), transferrin (20 µg ml -1 ; Figure 3D ), sodium selenite ( 20 ng ml -1; Figure 3E ), and FGF2-G3 (40 ng ml -1 ; Figure 3F ).
We next looked for alternatives to TGFβ1 as this was now the costliest component (~20% of total cost) and found that this could be used at lower concentrations than previously suggested (0.1 ng ml -1 ) even in a long-term assay (Figure S3A ). We found that other Activin/NODAL/TGFβ1 signaling sources such as NODAL were required at cost-prohibitively high levels (100 ng ml -1 ) (Figure 3G) , and Activin A was not suitable to maintain growth to the same level as TGFβ1 (Figure 3H) . Activin A in combination with TGFβ1 also has had a negative effect on growth (Figure S3B ). TGFβ1 is a homodimer of two TGFB1 gene products and therefore the recombinant protein is commonly produced in mammalian cells making it complex to produce for basic research labs. These mammalian cells provide post-translational modifications crucial for biological activity such as glycosylation, phosphorylation, proteolytic processing, and formation of disulfide bonds which are not present in E. coli. To overcome this issue, we generated a version of TGFβ1 (TGFβ1m) that is unable to form dimers due to a point mutation. This monomeric protein is predicted to be ~20-fold less potent than TGFβ1 but can be easily produced in large quantities in E. coli (Kim et al., 2015) . Our initial experiments demonstrated the TGFB1 sequence with E. coli-optimized codon usage was expressed in inclusion bodies. To overcome this, we inserted the sequence into a protein production plasmid (pET-32a) designed to produce a thioredoxin fusion protein allowing expression in the cytoplasm. It has been also demonstrated that TGFβ3 is more potent than TGFβ1 (Huang et al., 2014) . Comparing TGFβ1, TGFβ1m, TGFβ3, and TGFβ3m, we found that TGFβ3 offered the best combination of being able to be produced in E. coli and suitable for use at 0.1 ng ml -1 (Figures 3I, S3C , and S3D) and was therefore selected for the final formula.
Finally, two hESC media formulations that we studied, DC-HAIF and iDEAL, contain both FGF2 and neuregulin 1 (NRG1) (Figure S1B ). We found that supplementation with all tested levels of NRG1 enhanced growth by >15% over FGF2-G3 alone (Figures 3J and S3E) , although NRG1 is not able to support growth in the absence of FGF2 ( Figure S3F) . We similarly generated recombinant NRG1 protein using pET-32a, which prevented production as inclusion bodies, with subsequent cleavege using thrombin to form an active protein (Figures S3G and S4) . Our final B8 media formulation was derived from these long-term assay optimizations and is shown in Figure   3K .
Demonstration of the Suitability of B8 for hiPSC Generation and Weekend-Free Culture
The gold-standard demonstration of the suitability of a hiPSC media is the capacity to generate hiPSC lines. We generated hiPSC lines from 26 patients using established protocols but using B8.
Lines were successfully generated from all donors and passed standard assays for pluripotency including flow cytometry for SSEA4 and TRA-1-60 ( Figure 4A) , immunofluorescent staining for SSEA4, POU5F1, SOX2, and TRA-1-60 ( Figure 4B) , and karyotype stability ( Figure 4C) . We then compared this B8 formula ( Figure 3K ) with our traditional E8 formula and found that growth similar to B8 across commonly used split ratios ( Figure 4D ). It has been demonstrated that unlike commercial FGF2, thermostable variants of FGF2 such as FGF2-G3 are capable of inducing pERK in FGF-starved cells, even after media had previously been stored for extended periods at 37 °C Dvorak et al., 2018) . To confirm that our FGF2-G3 performed similarly we performed a comparable assay and corroborated that FGF2-G3 was stable after 7 days at 37 °C, whereas commercial FGF2 was not capable of stimulating pERK after 2 days at 37 °C. As common 'weekend-free' media formulae such as StemFlex have reverted to using albumin and likely contain heparin, both of which are not chemically defined, we also assessed the function of these components in this assay and found that both improved the stability of FGF2-G3 ( Figure 4E) .
With the understanding that B8 supports hiPSC growth across a variety of sub-optimal conditions (Figure 4D) , we established the suitability of this formula to skip days of media change.
We established a matrix of media change days both with and without thiazovivin ( Figure 5A ) and showed that daily B8 media changes (top row) was surprisingly the least suitable for growth rate.
B8T treatment without media changes was the least effective of the thiazovivin-containing protocols (bottom row), whereas B8T followed by B8 (dark grey bar) was a suitable compromise between growth rate and extended exposure to thiazovivin. With the knowledge of the influence of various media change-skipping timelines, we devised a 7-day schedule consisting of passaging cells every 3.5 days that would allow for the skipping of media changes on the weekends, a major caveat of current hiPSC culture protocols (Figures 5B and 5C ). Our data demonstrated that a 3.5day schedule with medium exchange after the first 24 h was suitable long-term, whereas no media exchange (i.e. passage only) was not suitable (Figure 5D ). In addition, supplementation of the media with 0.5 mg ml -1 of albumin did not rescue this deficit (Figure 5D ). Further experiments with various doses of albumin or heparin further confirmed that these do not have an additive effect in B8 ( Figure 5E ). One of the major caveats of skipping media changes is that differentiation efficiency and reproducibility is diminished. We used our existing cardiac (Burridge et al., 2014) , endothelial (Patsch et al., 2015) , and epithelial differentiation Qu et al., 2016) protocols to demonstrated that B8 supported differentiation to a similarly high level with either daily media change or our 7-day protocol (Figures 5F and 5G ).
Discussion
The hiPSC field predominantly utilizes two hiPSC culture media, the commercial mTeSR1 and Essential-8. Despite the formulae for these media being available to researchers, the complexity of media compounding and cost of growth factors required have made this unappealing. These two media, along with five other published hiPSC culture media formulae, have much in common due to their shared history ( Figure S1A ). Despite this, there are many media components that have not had their concentration optimized or necessity demonstrated. In many cases, especially the formulation of TeSR, optimization experiments were discussed yet no data were provided. In the experiments here we found that only five components were truly essential for hiPSC culture:
insulin, sodium selenite, FGF2, DMEM/F12, (Figure 1 ) and importance of a fifth component TGFβ1 was only evident in the long-term assay (Figures 1H, 3I, and S3A) . The other three components, ascorbic acid 2-phosphate, transferrin, and NRG1, are dispensable for hiPSC growth, although their removal results in a reduced growth rate.
During the development of this assay platform, we found that precise measurement of relative growth was a suitable surrogate for metrics of the pluripotent state (such as NANOG expression). When cells began to spontaneously differentiate, such as when TGFβ1 is omitted from the formula, the resulting slowing of growth was easily detectable. We noted a number of surprising results during this optimization. For example, we could not find a positive or negative effect of the addition of albumin ( Figure 2D ) despite it being a common constituent of many academic and commercial media formulae. We propose that high levels of ascorbic acid in our formula may have eliminated some of the need for the antioxidant role of albumin. We found that Activin A was not suitable either with or without TGFb1 (Figure 3H and S3B) despite its inclusion in a variety of other formulae. We do show that at very low doses Activin A could support growth, albeit to a lesser extent than TGFb1. In some media formulae, such as hESF9T, there is a positive correlation between higher levels of TGFb1 (up to 10 ng ml -1 ) and expression of NANOG (Yamasaki et al., 2014) while others have found only minimal differences above 0.1 ng ml -1 (Frank et al., 2012) . Similarly, it was shown that higher levels of HSA correlated with higher levels of POU5F1, SOX2, and NANOG (Frank et al., 2012) yet albumin-free formulae have been used extensively without issue. One of our major efforts during the development of B8 was the minimization of media costs.
13
In our previous E8-based formula, the growth factors FGF2 and TGFb1 represented more than 80% of the total medium costs and we found that this could be much higher if laboratories could not negotiate discounts from commercial recombinant protein suppliers ( Figure S5A) . The generation of recombinant proteins in-house, although daunting, was highly simplified by using three commercial products: MagicMedia for E. coli growth, B-PER for lysis, and Ni-NTA spin columns for purification. Combined, these eliminate much of the complexity for recombinant protein production, including the need for HPLC or FPLC. Each of these components could easily be replaced by more cost-effective procedures such as inducing protein expression using IPTG, making lysis buffers, or using higher-throughput columns, albeit with greater complexity. Our optimization of the plasmids and generation of thioredoxin fusion proteins where necessary eliminates much of the complexity associated with inclusion bodies and the resulting refolding processes otherwise required. A typical 1 liter E. coli culture, which requires two days and basic laboratory skills, will usually provide 80 mg of FGF2-G3, enough for 800 liters of B8. Similarly, a 500 ml culture of TGFb3 or NRG1 will commonly provide enough protein years of work (~800,000 liters of B8 media). This optimization leaves insulin and transferrin as the major remaining costs. We show that the concentrations of these components can be reduced by 75% without a substantial impact on growth rate (both at 5 µg ml -1 ) (Figure 3B and 3D) and based on these savings, have developed a formulation of B8 optimized for low-cost (Figure S5B and S5C) .
The difference between growth rate of hiPSC in either formula is likely undetectable in normal culture.
The final major cost is the basal media DMEM/F12 representing ~75% of the B8 formula ( Figure S5A) . It is simple to generate DMEM/F12 from powder to reduce costs, although the requirement for suitable water quality and filter sterilization adds complexity to the media making process and therefore may not be appropriate for all but the highest usage labs. DMEM/F12 is a combination of 52 amino acids, vitamins, inorganic salts, and other components derived from DMEM, a high nutrient (amino acid and vitamin) concentration media, originally optimized for fibroblast growth, and F12, a rich and complex fatty acid-containing media optimized for CHO cells to generate a complex 'catch-all' formula. Few experiments have been completed to compare alternatives to DMEM/F12 for hiPSC culture, indeed, Chen et al. showed comparable results between DMEM/F12 and the comparatively simple MEMa, suggesting that there is much to learn in this respect. hiPSC culture without daily media changes introduces a number of potential caveats, for example, we know that the L-glutamine in the medium is unstable at 37 °C and that the concentration is reduced by about a third over four days. We also know that cells are producing ammonia, reducing the pH of the media, although this buffered partially by the HEPES and sodium bicarbonate. Finally, hiPSCs release autocrine or paracrine factors into the media that may induce differentiation and the increase in these factors over time has not been decoupled from the use of nutrients and production of metabolic waste. We chose not to maintain exposure to Rho-associated kinase (ROCK1/2) inhibitors as there exists data suggesting that this induces epithelial-tomesenchymal transition (Maldonado et al., 2016) . Furthermore, ROCK inhibitors have a widerange of off-target effects (Andrews et al., 2010) . These issues may result in undesired effects although this remains to be validated experimentally and formulations do exist that maintain constant ROCK1/2 inhibitor exposure (Tsutsui et al., 2011) .
As hiPSC projects become larger and move beyond proof-of-principle experiments, the labor required to maintain cells becomes burdensome, especially the need for daily media changes 7-days a week. Here we show that our B8 formula is well-suited to weekend-free schedules. A major issue with some commercial media is that although a weekend-free schedule is feasible, growth of hiPSCs is considerably slower and it is recommended to grow cells as low-density colonies. These low-density colonies are not compatible with subsequent monolayer
Experimental Procedures

Human Induced Pluripotent Cell Culture
All pluripotent and reprogramming cell cultures were maintained at 37 ºC in Heracell VIOS 160i direct heat humidified incubators (Thermo Scientific) with 5% CO2 and 5% O2. Differentiation cultures were maintained at 5% CO2 and atmospheric (~21%) O2. All cultures (pluripotent and differentiation) were maintained with 2 ml medium per 9.6 cm 2 of surface area or equivalent. All media was used at 4 °C and was not warmed to 37 °C before adding to cells due to concerns of the thermostability of the FGF2 . We have found no detectable effects on cell growth from using cold media. All cultures were routinely tested for mycoplasma using a MycoAlert PLUS Kit (Lonza) and a 384-well Varioskan LUX (Thermo Scientific) plate reader.
E8 medium was made in-house as previously described (Burridge et al., 2015; Chen et al., 2011) and consisted of DMEM/F12 (Corning, 10-092-CM), 20 μg ml -1 E. coli-derived recombinant human insulin (Gibco, A11382IJ), 64 μg ml -1 L -ascorbic acid 2-phosphate trisodium salt (Wako, 321-44823), 10 μg ml -1 Oryza sativa-derived recombinant human transferrin (Optiferrin, InVitria, 777TRF029-10G,), 14 ng ml -1 sodium selenite (Sigma, S5261), 100 ng ml -1 recombinant human FGF2-K128N (made in-house, see below), 2 ng ml -1 recombinant human TGFβ1 (112 amino acid, HEK293-derived, Peprotech, 100-21). Cells were routinely maintained in E8 medium on 1:800 diluted growth factor reduced Matrigel (see below). E8 was supplemented with 10 μM Y27632 dihydrochloride (LC Labs, Y-5301), hereafter referred to as E8Y, for the first 24 h after passage.
For standard culture, cells were passaged at a ratio of 1:20 every 4 days using 0.5 mM EDTA (Invitrogen UltraPure) in DPBS (without Ca 2+ and Mg 2+ , Corning), after achieving ~70-80% confluence. Cell lines were used between passages 20 and 100. Other media components tested were: Human Long R3 IGF1 (Sigma, 91590C), thiazovivin (LC Labs, T-9753), recombinant human TGFβ3 (Cell Guidance Systems, GFH109), sodium bicarbonate (Sigma), NEAA (Gibco), CD Lipids (Gibco), fatty acid-free albumin (GenDEPOT, A0100). pH was adjusted with 10N HCl or 1N NaOH (both from Sigma) and measured using a SevenCompact pH meter (MettlerToledo).
Osmolarity was adjusted with sodium chloride (Sigma) or cell culture water (Corning) and measured with an osmometer (Advanced Instruments).
Matrigel Optimization
Our standard condition throughout was 2 ml of 1:800 reduced growth factor Matrigel (Corning, 354230) diluted in 2 ml of DMEM (Corning, 10-017-CV) per well of 6-well plate or equivalent.
Also tested were Geltrex (Gibco) and Cultrex (Trevigen). Plates were made and kept in incubators at 37 °C for up to one month.
FGF2-K128N Generation
The full length (154 amino YVGRTPKVEQ LSNMVVKSCK CS was codon optimized for E. coli and generated as above, ligated in to a pET-32a expression vector, and cloned in to One Shot BL21 Star (DE3). The use of pET-32a results in the production of a thioredoxin-TGFBβ3 fusion protein which prevents protein expression in inclusion bodies. It is not necessary to cleave the thioredoxin for TGFBβ3 to be active. TGFβ1, TGFβ1m (C77S), and TGFβ3m (C77S) were similarly generated.
NRG1 Generation
65 amino acid sequence: SHLVKCAEKE KTFCVNGGEC FMVKDLSNPS RYLCKCPNEF TGDRCQNYVM ASFYKHLGIE FMEAE, which is a truncated version of NRG1 containing just the EGF domain, was codon optimized for E. coli and generated as above, ligated in to a pET-32a expression vector, and cloned in to One Shot BL21 Star (DE3). The use of pET-32a results in the production of a thioredoxin-NRG1 fusion protein which prevents protein expression in inclusion bodies. It was found necessary to cleave the thioredoxin using Thrombin CleanCleave Kit (MilliporeSigma), followed by repurification, keeping the supernatant.
Media Variable Optimization Protocol
The hiPSC line 19-3 was dissociated with TrypLE (Gibco, 12604-013) for 3 min at 37 °C and cells were resuspended in DMEM/F12, transferred to a 15 ml conical tube (Falcon) and centrifuged at 200 ´ g for 3 min (Sorvall ST40). The pellet was resuspended in DMEM/F12, diluted to 1 ´ 10 5 cells per ml and 10,000 cells were plated per well in Matrigel (1:800)-coated 12-well plates (Greiner) in the medium to be tested along with 2 µM thiazovivin for the first 24 h. Media were changed daily and cells were grown for 6 days. This lower than normal seeding density was used to allow the discovery of factors only detectable under more extreme conditions and therefore provide data on the robustness to the formulation.
Western Blot
Stock lysis buffer was prepared as 150 mM NaCl, 20 mM Tris pH 7.5, 1 mM EDTA, 1 mM EGTA, TBST and reblocked with 5% BSA for 30 min.
Human Induced Pluripotent Stem Cell Derivation
Protocols were approved by the Northwestern University Institutional Review Boards. With informed written consent, ~9 ml of peripheral blood was taken from each volunteer and stored at 4 ºC, samples were transferred to Leucosep tubes (Greiner) filled with Histopaque-1077 (Sigma). 1 x 10 6 isolated peripheral blood mononuclear cells (PMBC) were grown in 24-well tissue culturetreated plates (Greiner) in 2 ml of SFEM II (Stem Cell Technologies) supplemented with 10 ng ml -1 IL3, 50 ng ml -1 SCF (KITLG), 40 ng ml -1 IGF1 (all Peprotech), 2 U ml -1 EPO (Calbiochem), 1 μM dexamethasone (Sigma) (Chou et al., 2015) . 50% medium was changed every other day.
After 12 days of growth, 6 x 10 4 cells were transferred to a well of a 24-well plate in 500 μL of 22 SFEM II with growth factors supplemented with CytoTune-iPS 2.0 Sendai Reprogramming Kit viral particle factors (Gibco) (Fujie et al., 2014; Fusaki et al., 2009) Advanced software.
Population Doubling Level Assessment
Population doubling level (PDL) was calculated according to the following formula:
PDL = 3.32[log10(n/n0)]
Where n = cell number and n0 = number of cells seeded
Cardiac Differentiation
Differentiation into cardiomyocytes was performed according to previously described protocol with slight modifications (Burridge et al., 2015; Burridge et al., 2014) . Briefly, hiPSCs were split at 1:20 ratios using 0.5 mM EDTA as above and grown in B8 medium for 4 days reaching ~75%
confluence. At the start of differentiation (day 0), B8 medium was changed to CDM3 (chemically defined medium, three components) (Burridge et al., 2014) , consisting of RPMI 1640 (Corning, 10-040-CM), 500 μg ml -1 fatty acid-free bovine serum albumin (GenDEPOT), and 200 μg ml -1 Lascorbic acid 2-phosphate (Wako). For the first 24 h, CDM3 medium was supplemented with 6 μM of glycogen synthase kinase 3-b inhibitor CHIR99021 (LC Labs, C-6556). On day 1, medium was changed to CDM3 and on day 2 medium was changed to CDM3 supplemented with 2 μM of the Wnt inhibitor Wnt-C59 (Biorbyt, orb181132). Medium was then changed on day 4 and every other day for CDM3. Contracting cells were noted from day 7. On day 14 of differentiation, 24 cardiomyocytes were dissociated using DPBS for 20 min at 37 °C followed by 1:200 Liberase TH (Roche) diluted in DPBS for 20 min at 37 °C, centrifuged at 300 g for 5 min, and filtered through a 100 μm cell strainer (Falcon).
Endothelial Differentiation
hiPSCs were grown to approximately 50-70% confluent and differentiated according to an adapted version of a protocol previously described (Patsch et al., 2015) . On day 5 of differentiation, endothelial cells were dissociated with Accutase (Gibco) for 5 min at 37 °C, centrifuged at 300 g for 5 min, and analyzed.
Epithelial Differentiation
hiPSCs were split at 1:20 ratios using 0.5 mM EDTA as above and grown in B8T medium for 1 day reaching ~15% confluence at the start of differentiation. Surface ectoderm differentiation was performed according to an adapted version of previously described protocols Qu et al., 2016) . On day 4 of differentiation, epithelial cells were dissociated with Accutase (Gibco) for 5 min at 37 °C, centrifuged at 300 g for 5 min, and analyzed.
Differentiated Cell Flow Cytometry
Cardiomyocytes were dissociated with Liberase TH as described above, transferred to flow 
Statistical Methods
Data were analyzed in Excel or R and graphed in GraphPad Prism 8. Detailed statistical information is included in the corresponding figure legends. Data were presented as mean ± SEM.
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B8T (1) - Figure 3I , TGFb3 (in-house). (E) Addition of commercial NRG1 to FGF2-G3-containing media (n > 5). (F) Relative growth in medium with NRG1 but without FGF2, long-term assay (n = 5). (G) in-house NRG1 with thrombin fusion protein cleaved by two different methods, shortterm assay (n = 8) (compare to Figure 2J, commercial NRG1) . Figure S4 . DNA Sequences used to Generate Growth Factor Plasmids. Note that FGF2-G3 and TGFb3 were shown to function without the need for cleavage of N-terminus 6xHis tag/fusion proteins therefore C-terminus stop codons were also removed to read through to an additional 6xHis tag to enhance purification efficiency.
Generating B8 supplements (for 100 l)
Shown below are directions for making 100 × B8 supplement aliquots suitable for generated 100 liters of B8. B8 contains high levels of ascorbic acid and therefore must be made as a two-aliquot system. Aliquot 1: 400 mg ml -1 L-ascorbic acid 2-phosphate: Add 50 ml of room temperature cell culture water (Corning) to a 50 ml Falcon tube, then slowly add 20 g of L-ascorbic acid 2-phosphate. Mix by inversion until clear, filter sterilize (PES 0.2 µm filters) and make 100 x 500 µl aliquots in sterile 1.5 ml microfuge tubes and store at -20°C.
Aliquot 2:
Place 46 ml of room temperature cell culture water in a 50 ml Falcon tube, add 2 g (or 0.5 g) of insulin, add 1400 µl (or 350 µl) of 1 N HCl to dissolve (~pH 3), mix until clear and then add 200 µl (or 50 µl) 10 N NaOH (~pH 7.4), then add 2 g (or 0.5 g) of transferrin, 1 mL of 2 mg ml -1 sodium selenite, 400 µl of 10 mg ml -1 FGF2-G3, 100 µl of 100 µg ml -1 TGFb3, and 100 µl of 100 µg ml -1 NRG1. Mix by inversion until clear, filter sterilize (PES 0.2 µm filters) and make 500 µl aliquots in sterile 1.5 ml microfuge tubes and store at -20°C.
To make a 1 l bottle of B8 thaw one aliquot at RT and aseptically add to 1 l of DMEM/F12 along with 72 ml of cell culture water (to bring osmolarity to 310 mOsm). 
